NewAmsterdam Pharma - NAMS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $33.25
  • Forecasted Upside: 76.67%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$18.82
▼ -0.28 (-1.47%)

This chart shows the closing price for NAMS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NewAmsterdam Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NAMS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NAMS

Analyst Price Target is $33.25
▲ +76.67% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for NewAmsterdam Pharma in the last 3 months. The average price target is $33.25, with a high forecast of $37.00 and a low forecast of $30.00. The average price target represents a 76.67% upside from the last price of $18.82.

This chart shows the closing price for NAMS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in NewAmsterdam Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2024TD CowenInitiated CoverageBuyLow
3/14/2024ScotiabankInitiated CoverageSector Outperform ➝ Sector Outperform$35.00Low
2/29/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$25.00 ➝ $31.00Low
1/18/2024GuggenheimInitiated CoverageBuy$30.00Low
1/16/2024Piper SandlerInitiated CoverageOverweight$37.00Low
11/22/2023William BlairReiterated RatingOutperformLow
10/30/2023Royal Bank of CanadaInitiated CoverageOutperform$25.00Low
4/3/2023Credit Suisse GroupBoost TargetOutperform$21.00 ➝ $22.00Low
1/6/2023Credit Suisse GroupInitiated CoverageOutperform$21.00Low
12/20/2022SVB LeerinkInitiated CoverageOutperform$19.00Low
12/19/2022William BlairInitiated CoverageOutperformLow
12/19/2022Jefferies Financial GroupInitiated CoverageBuy$24.00Low
(Data available from 5/25/2019 forward)

News Sentiment Rating

-0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/28/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/27/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/26/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
2/25/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/26/2024
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
5/25/2024

Current Sentiment

  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
NewAmsterdam Pharma logo
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Read More

Today's Range

Now: $18.82
Low: $18.51
High: $20.33

50 Day Range

MA: $21.05
Low: $18.82
High: $23.65

52 Week Range

Now: $18.82
Low: $5.63
High: $26.35

Volume

131,706 shs

Average Volume

117,734 shs

Market Capitalization

$1.69 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.08

Frequently Asked Questions

What sell-side analysts currently cover shares of NewAmsterdam Pharma?

The following sell-side analysts have issued research reports on NewAmsterdam Pharma in the last twelve months: Guggenheim, Piper Sandler, Royal Bank of Canada, Scotiabank, TD Cowen, and William Blair.
View the latest analyst ratings for NAMS.

What is the current price target for NewAmsterdam Pharma?

4 Wall Street analysts have set twelve-month price targets for NewAmsterdam Pharma in the last year. Their average twelve-month price target is $33.25, suggesting a possible upside of 76.7%. Piper Sandler has the highest price target set, predicting NAMS will reach $37.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $30.00 for NewAmsterdam Pharma in the next year.
View the latest price targets for NAMS.

What is the current consensus analyst rating for NewAmsterdam Pharma?

NewAmsterdam Pharma currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NAMS will outperform the market and that investors should add to their positions of NewAmsterdam Pharma.
View the latest ratings for NAMS.

What other companies compete with NewAmsterdam Pharma?

How do I contact NewAmsterdam Pharma's investor relations team?

NewAmsterdam Pharma's physical mailing address is TWO UNION SQUARE 601 UNION STREET SUITE 3200, SEATTLE WA, 98101. The company's listed phone number is 352062971 and its investor relations email address is [email protected]. The official website for NewAmsterdam Pharma is www.newamsterdampharma.com. Learn More about contacing NewAmsterdam Pharma investor relations.